Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

JAMA

Volumn 291, Issue 24, 2004, Pages 2947-2958

  Shumaker, Sally A ^a   Legault, Claudine ^b   Kuller, Lewis ^b   Rapp, Stephen R ^b   Thal, Leon ^b   Lane, Dorothy S ^b   Fillit, Howard ^b   Stefanick, Marcia L ^b   Hendrix, Susan L ^b   Lewis, Cora E ^b   Masaki, Kamal ^b   Coker, Laura H ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; PLACEBO; MEDROXYPROGESTERONE ACETATE;

AGED; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MODIFIED MINI MENTAL STATE EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; PROBABLE DEMENTIA; RANDOMIZED CONTROLLED TRIAL; RISK; ESTROGEN THERAPY; PROPORTIONAL HAZARDS MODEL;

AGED; COGNITION DISORDERS; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INCIDENCE; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 2942755831     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.24.2947     Document Type: Article

References (50)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
2. Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385-1389.
3. Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179-1184.
4. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparison between Alzheimer disease cases and nondemented control groups. Arch Neurol. 1994;51:896-900.
5. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999;52:965-970.
6. Steffens DC, Norton MC, Plassman BL, et al. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J Am Geriatr Soc. 1999;47:1171-1175.
7. Kawas C, Resnick SM, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer disease: the Baltimore Longitudinal Study on Aging. Neurology. 1997; 48:1517-1521.
8. Tang MX, Jacobs D, Stern Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer disease. Lancet. 1996;348:429-432.
9. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368-373.
10. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279: 688-695.
11. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement: scientific review. JAMA. 2002;288:872-881.
12. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc. 1999; 47:518-523.
13. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637-2641.
14. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301.
15. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA. 2000;283:1007-1015.
16. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061-2066.
17. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485-512.
18. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
19. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19:604-621.
20. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
21. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291:1701-1712.
22. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
23. Teng EL, Chui H. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48:314-318.
24. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
25. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part I: clinical and neuropsychological assessment of Alzheimer disease. Neurology. 1989; 39:1159-1165.
26. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA. 1994;272:1749-1756.
27. Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol. 1991;4:173-178.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
29. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58:1985-1992.
30. Ganguli M, Belle S, Ratclliff G, et al. Sensitivity and specificity for dementia of population-based criteria for cognitive impairment: the MOVIES project. J Gerontol. 1993;48:M152-M161.
31. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
32. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev. 2003;24:133-151.
33. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonln neural system. Front Neuroendocrinol. 2002;23:41-100.
34. Linzmayer L, Semlitsch HV, Saletu B, et al. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung. 2001;51:238-245.
35. US Food and Drug Administration. FDA Updates Hormone Therapy Information for Post Menopausal Women. Available at: http://www.fda.gov /bbs/topics/NEWS/ 2004/NEW01022.html.
36. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and the incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288:2123-2129.
37. Beck TJ, Stone KL, Oreskovic TL, et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the Study of Osteoporotic Fractures. J Bone Miner Res. 2001;16:2103-2110.
38. Gibbs RB. Estrogen replacement enhances acquisition of a spatial memory task and reduces deficits associated with hippocampal muscarinic receptor inhibition. Horm Behav. 1999;36:222-233.
39. Rapp PR, Morrison JH, Roberts JA. Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. J Neurosci. 2003; 23:5708-5714.
40. Petersen RC, Jack CR Jr, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology. 2000;54:581-587.
41. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33:21-25.
42. Bryan RN, Wells SW, Miller TJ, et al. infarctlike lesions in the brain: prevalence and anatomic characteristics at MR imaging of the elderly-data from the Cardiovascular Health Study. Radiology. 1997;202: 47-54.
43. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
44. Kuller LH, Lopez OL, Newman A, et al. Risk factors for dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology. 2003;22:13-22.
45. Swan GE, DeCarli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51:986-993.
46. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
47. Longstreth WT Jr, Dulberg C, Manolio TA, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke. 2002;33:2376-2382.
48. Neuropathology Group of the Medical Research Council Cognitive Function and Aging Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre community-based population in England and Wales. Lancet. 2001;357:169-175.
49. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813-817.
50. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34:335-337.